Do Kim
Stock Analyst at Piper Sandler
(2.07)
# 2,801
Out of 4,853 analysts
92
Total ratings
44.93%
Success rate
3.01%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $35.24 | +78.77% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $14.72 | +212.50% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $443.82 | -33.31% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $110.46 | +1.39% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $23.84 | +264.93% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $2.26 | +917.70% | 2 | Jan 19, 2023 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $20.97 | -4.63% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $9.75 | +341.03% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $42.37 | -24.47% | 1 | Jul 26, 2022 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $21 → $22 | $2.37 | +828.27% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $34.25 | -44.53% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $2.48 | +545.16% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $308.00 | -39.94% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $9.90 | +8,990.91% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $53.55 | -34.64% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $1.34 | +1,392.54% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $35.24
Upside: +78.77%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $14.72
Upside: +212.50%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $443.82
Upside: -33.31%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $110.46
Upside: +1.39%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $23.84
Upside: +264.93%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $2.26
Upside: +917.70%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $20.97
Upside: -4.63%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $9.75
Upside: +341.03%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $42.37
Upside: -24.47%
AbCellera Biologics
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $2.37
Upside: +828.27%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $34.25
Upside: -44.53%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $2.48
Upside: +545.16%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $308.00
Upside: -39.94%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $9.90
Upside: +8,990.91%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $53.55
Upside: -34.64%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $1.34
Upside: +1,392.54%